Sage Journals: Discover world-class research

Abstract

Long non-coding RNA (lncRNA) small nucleolar RNA host gene 12 (SNHG12) has been reported to participate in the regulation of various nervous system disorders. Bupivacaine (BV), a commonly used local anesthetic, could generate neurotoxicity in neurons. This work intended to investigate the role and specific mechanism of SNHG12 in BV-induced neurotoxicity. In this study, we established an in vitro cell model of BV-induced neurotoxicity by exposing human neuroblastoma cells (SH-SY5Y) to BV. It was found that SNHG12 and NLRX1 levels were gradually downregulated, while miR-497–5p enrichment was upregulated accordingly with the increase of BV concentration. As indicated by functional assays, SNHG12 overexpression promoted cell viability but inhibited cell apoptosis and oxidative stress in BV-treated SH-SY5Y cells. In addition, it was identified that SNHG12 directly targeted miR-497–5p and attenuated BV-induced neurotoxicity via interaction with miR-497–5p. Besides, it was confirmed that SNHG12 could upregulate NLRX1 expression by absorbing miR-497–5p. Moreover, miR-497–5p decreased cell viability and induced cell apoptosis and oxidative stress, which was partly reversed by NLRX1 upregulation. In conclusion, our findings indicated that SNHG12 might relieve BV-associated neurotoxicity by upregulating NLRX1 via miR-497–5p in vitro, providing novel clues and biomarkers for the treatment and prevention of BV-associated neurotoxicity.

Keywords

SNHG12 Bupivacaine neurotoxicity miR-497–5p NLRX1

Introduction

Bupivacaine (BV) is a kind of anesthetic extensively applied for long-term local anesthesia during labor, surgery, or certain medical procedures.¹ According to previous reports, adverse drug reactions of BV administration could result in severe and even irreversible damage to the central nervous system and cardiovascular system of patients.^2–4 Increasing evidence has shown that BV could induce neurotoxicity through diverse signaling pathways.^5,6 Nevertheless, few studies have investigated the molecular mechanisms of BV-induced neurotoxicity.

Long non-coding RNAs (lncRNAs) are a group of non-protein-coding RNAs containing more than 200 nucleotides.⁷ Many reports have shown that lncRNAs can participate in several biological processes and cellular activities, including apoptosis,⁸ proliferation,⁹ autophagy,¹⁰ inflammation,¹¹ and oxidative stress response.¹² Besides, the dysregulation of lncRNAs is associated with the development and progression of various human diseases, including anesthesia-induced neurotoxicity.¹³ For example, Yao et al. disclosed that KCNQ1OT1 alleviated anesthesia-induced neurotoxicity through the miR-206/BDNF pathway.¹⁴ Besides, He et al. showed that BACE1-AS knockdown relieved isoflurane-induced neurotoxicity in Alzheimer’s disease via targeting miR-214–3p.¹⁵ The functions of the small nucleolar RNA host gene (SNHG) family in regulating the biological activities of nerve cells have been widely reported. To cite an instance, Zhang et al. demonstrated that SNHG1 aggravated sevoflurane-induced neurotoxicity via interaction with miR-181b.¹⁶ Zhang et al. uncovered that SNHG7 induced inflammatory response and apoptosis in a cell model of Parkinson’s disease (PD).¹⁷ Besides, Pan et al. affirmed the neuroprotective role of SNHG16 in a cellular model of cerebral ischemic/reperfusion (I/R).¹⁸ LncRNA SNHG12, a member of the SNHG family, is located in the p35.3 region of chromosome 1.¹⁹ As revealed by Yan et al. in a former study, SNHG12 could depress neuronal apoptosis caused by oxygen-glucose deprivation (OGD) treatment through upregulating NEGR1 expression via interaction with miR-181a-5p.²⁰ In addition, Yao et al. found SNHG12 played a neuroprotective role in cerebral I/R injury by inducing autophagy in nerve cells.²¹ Also, Yan et al. demonstrated that SNHG12 could regulate neuronal apoptosis and inflammatory responses in PD via the miR-138–5p/NFIB axis.²² However, the function of SNHG12 in BV-induced neurotoxicity is still unclear.

In the current work, we investigated whether and how SNHG12 participated in BV-induced neurotoxicity. Through a series of functional assays and bioinformatics analysis, we found that SNHG12 played a neuroprotective role against BV-induced neurotoxicity via the miR-497–5p/NLR family member X1 (NLRX1) axis, offering novel targets for preventing or treating BV-induced neurotoxicity.

Materials and Methods

Reagents

The human neuroblastoma cell line (SH-SY5Y) was purchased from Bena Culture Collection (BNCC338056, Suzhou, China). Dulbecco’s modified Eagle medium (DMEM) and fetal bovine serum (FBS) were purchased from Gibco Company (Grand Island, USA). Bupivacaine and dimethyl sulfoxide (DMSO) were purchased from Sigma-Aldrich (St Louis, USA). All reagents used in RT-qPCR were purchased from Invitrogen (USA) or Takara (Japan). All RT-qPCR primers were obtained from Sangon Biotech (Shanghai, China). Other reagents are as follows: CCK-8 reagents (Beyotime, China), Annexin V-fluorescein isothiocyanate (V-FITC) and propidium iodide (PI) (KeyGEN, China), Lactate dehydrogenase (LDH), superoxide dismutase (SOD), malondialdehyde (MDA), and glutathione peroxidase (GSH-Px) commercial kits (Nanjing Jiancheng Bioengineering Institute, China).

Cell culture and BV treatment

SH-SY5Y cells were cultured in DMEM containing 10% FBS and 1% penicillin/streptomycin in an incubator (37°C 5%; CO₂). For BV treatment, BV was first dissolved in DMSO. Then, SH-SY5Y cells were incubated with BV at different concentrations (0, 0.5, 1.0, 1.5, or 2.0 mM) for 24 h as described previously.²³ Cells at passage four were used for subsequent analysis.

Cell transfection

SNHG12 overexpression vector (oe-SNHG12), pcDNA3.1 empty vector (Vector), small interfering RNA (siRNA) against SNHG12 (si-SNHG12) or NLRX1 (si-NLRX1), negative control (si-NC), miR-497–5p mimics, miR-497–5p inhibitor, and corresponding negative controls (NC mimics and NC inhibitor) were all synthesized by GenePharma. Then, the above-mentioned plasmids were transfected into SH-SY5Y cells using Lipofectamine 2000 (Invitrogen, USA). After 48 h’ transfection, the cells were harvested for subsequent experiments.

CCK-8 assay

CCK-8 assay was applied for the assessment of cell viability. SH-SY5Y cells were plated into 96-well plates (1 × 10⁴ cells/well) and incubated with different BV concentrations (0, 0.5, 1.0, 1.5, or 2.0 mM) for 24 h. Thereafter, 10 μL CCK-8 solution was added to each well, and the cells were cultured at 37°C for another 2 h. Via a microplate reader (BioTek Instruments, USA), the optical density at 450 nm was detected.

Flow cytometry

Flow cytometry assay was applied to detect cell apoptosis. Briefly, treated SH-SY5Y cells were collected, rinsed with PBS, resuspended in 200 μL Annexin V-binding buffer, and then stained with Annexin V-FITC and PI for 15 min in darkness. The apoptotic cells were measured by an FCM flow cytometer with FlowJo software (BD Bioscience, USA). Q1 = Necrosis, Q2 = Late apoptosis, Q3 = Early apoptosis, Q4 = Viability.

Determination of oxidative stress-associated factors

The SH-SY5Y cell supernatants were harvested after treatment. LDH, SOD, MDA, and GSH-Px levels were measured with corresponding commercial kits (Nanjing Jiancheng Bioengineering Institute, China) as per the standard protocol.

RT-qPCR assay

The total RNA extraction was conducted with TRIzol reagent (Invitrogen, USA). Total RNA was reversely transcribed into cDNA with PrimeScript RT Reagent Kit (Takara, Japan). Thereafter, qPCR was performed with SYBR Green kit on ABI 7500 Real-time PCR system (Applied Biosystems). The relative gene expressions were calculated by 2^−ΔΔCt method. GAPDH or U6 was utilized as the internal control. The primers used were listed below: SNHG12: 5^′-GGTGCTCCAGGCAATAACT-3^′ (forward: F), 5^′-CTCCCATACAGTCCGAACAT-3^′SNHG12 (reverse: R); NLRX1: 5^′-TAGGGCCTTTATCCGTTACCA-3^′ (F), 5^′-TAAACCACTCGGTGAGGTTCC-3^′ (R); BDNF: 5^′-GAAAGTCCCGGTATCAAAAG-3^′ (F), 5^′-CGCCAGCCAATTCTCTTTTTG-3^′ (R); GAPDH: 5^′-ACCCACTCCTCCACCTTTGAC-3^′ (F), 5^′-TGTTGCTGTAGCCAAATTCGTT-3^′ (R); miR-497–5p: 5^′-CCTTCAGCAGCACACTGTGG-3^′ (F), 5^′-CAGTGCAGGGTCCGAGGTAT-3^′ (R); U6: 5^′-GCTTCGGCAGCACATATACTAAAAT-3' (F), 5^′-CGCTTCACGAATTTGCGTGTCAT-3' (R).

Dual-luciferase reporter assay

DNA fragments of SNHG12 or 3^′-UTR NLRX1 with wildtype (WT) or mutant (Mut) binding sequences for miR-497–5p were subcloned into pGL3 vectors to construct corresponding plasmids (SNHG12-WT, SNHG12-MUT, NLRX1-WT, and NLRX1-MUT). The above plasmids were transfected into SH-SY5Y cells, respectively, together with NC mimics or miR-497–5p mimics. After 48 h, the luciferase activity of SH-SY5Y cells in each group was assessed via the Dual-Luciferase Reporter Assay Kit (Promega, USA).

Statistical analysis

Data were acquired from at least three repeated experiments and presented as mean ± standard deviation (SD). GraphPad Prism 6.0 was applied for statistical analysis of differences via one-way ANOVA (more than two groups) or Student’s t-test (two groups). p-value < 0.05 was defined as significant in statistics.

Results

SNHG12 is lowly expressed in an in vitro model of BV-induced neurotoxicity

To explore the regulatory mechanism of BV-induced neurotoxicity, a BV-induced cell model was constructed by treating SH-SY5Y cells with BV at different concentrations (0, 0.5, 1.0, 1.5, or 2.0 mM). As shown by CCK-8 assay, BV treatment markedly suppressed the viability of SH-SY5Y cells (Figure 1(A)). Since 1.0 mM BV concentration could trigger approximately 50% cell growth inhibition in SH-SY5Y cells, 1.0 mM BV concentration was applied for subsequent function assays. Flow cytometry assay exhibited that BV treatment significantly increased apoptosis in SH-SY5Y cells (Figure 1(B)). Next, morphological changes in SH-SY5Y cells were observed. As indicated in Figure 1(C), after exposure to BV (1.0 mM) for 24 h, SH-SY5Y cells became round and were atrophic in shape and incomplete in structure. In addition, the levels of oxidative stress-associated factors (LDH, MDA, SOD, and GSH-Px) were also detected. The results manifested that LDH and MDA levels were elevated, while SOD and GSH-Px levels were declined in BV-treated SH-SY5Y cells (Figure 1(D–G)), indicating that BV treatment led to oxidative stress damage in SH-SY5Y cells. As an important biomarker to evaluate neurotoxicity, the brain-derived neurotrophic factor (BDNF) level was also measured by RT-qPCR. The results showed that the BDNF level in SH-SY5Y cells was dramatically decreased after BV challenge (Figure 1(H)). As evidenced by the attenuated cell viability, the increased cell apoptosis rate and oxidative stress damage, and the decreased BDNF level in SH-SY5Y cells caused by BV treatment, it was shown that BV treatment could lead to neurotoxicity, indicating the successful establishment of the in vitro model of BV-induced neurotoxicity. Furthermore, RT-qPCR results revealed that SNHG12 expression was declined in SH-SY5Y cells with the increase of BV concentration (Figure 1(I)). Therefore, it was speculated that SNHG12 might be involved in the BV-induced cytotoxicity in SH-SY5Y cells.

Figure 1.

SNHG12 is lowly expressed in an in vitro model of BV-induced neurotoxicity. (A) SH-SY5Y cells were treated with BV at different concentrations (0, 0.5, 1.0, 1.5, or 2.0 mM). CCK-8 assay was applied to assess the viability of SH-SY5Y cells. (B) Flow cytometry assay was applied to detect SH-SY5Y cell apoptosis. Q1 = Necrosis, Q2 = Late apoptosis, Q3 = Early apoptosis, Q4 = Viability. (C) Effect of BV on cell morphology. (D–G) The levels of oxidative stress-associated factors (including LDH, MDA, SOD, and GSH-P_X) in SH-SY5Y cells were detected by specific kits. (H) BDNF level in SH-SY5Y cells from each group was detected via RT-qPCR. (I) SNHG12 expression in SH-SY5Y cells treated with BV at different concentrations (0, 0.5, 1.0, 1.5, or 2.0 mM) was detected via RT-qPCR assay. * p < 0.05, ** p < 0.01.

SNHG12 upregulation alleviates the neurotoxicity induced by BV treatment in SH-SY5Y cells

To analyze the regulatory function of SNHG12 in BV-induced neurotoxicity, a series of gain-of-function assays were applied. First of all, SNHG12 was overexpressed in SH-SY5Y cells and the overexpression efficiency was assessed via RT-qPCR (Figure 2(A)). Then, SH-SY5Y cells were firstly subject to BV treatment and then transfected with Vector or oe-SNHG12. As exhibited in Figure 2(B), SNHG12 expression was decreased after BV treatment, while SNHG12 upregulation partly abolished the suppressive effect (Figure 2(B)). CCK-8 assay results showed that BV treatment led to a remarkable inhibitory effect on SH-SY5Y cell viability, while SNHG12 overexpression markedly restored this reduction in SH-SY5Y cells (Figure 2(C)). Flow cytometry showed that the apoptotic rate of SH-SY5Y cells was remarkably enhanced after BV treatment; however, this impact was partly abrogated by SNHG12 upregulation (Figure 2(D)). In addition, SNHG12 addition also distinctly eliminated the impact of BV treatment on LDH, MDA, SOD, and GSH-Px levels (Figure 2(E–H)), suggesting SNHG12 upregulation could eliminate BV-induced oxidative stress damage in SH-SY5Y cells. Moreover, BV-mediated decline in BDNF level was partly reversed by SNHG12 addition (Figure 2(I)). The above data indicated that SNHG12 improved BV-induced neurotoxicity in vitro.

Figure 2.

SNHG12 upregulation alleviates the neurotoxicity induced by BV treatment in SH-SY5Y cells. (A) SNHG12 expression in SH-SY5Y cells transfected with Vector or oe-SNHG12 was detected via RT-qPCR assay. (B) SH-SY5Y cells were firstly subject to BV treatment and then transfected with Vector or oe-SNHG12, with untreated SH-SY5Y cells as the control group. SNHG12 expression in SH-SY5Y cells from Control, BV+Vector, or BV+oe-SNHG12 group was assessed via RT-qPCR. (C) CCK-8 assay was applied to assess the viability of SH-SY5Y cells in Control, BV+Vector, or BV+oe-SNHG12 groups. (D) Flow cytometry assay was applied to detect SH-SY5Y cell apoptosis in each group. Q1 = Necrosis, Q2 = Late apoptosis, Q3 = Early apoptosis, Q4 = Viability. (E–H) The LDH, MDA, SOD, and GSH-P_X levels in SH-SY5Y cells were detected by specific kits. (I) BDNF level in SH-SY5Y cells from each group was detected via RT-qPCR. * p < 0.05, ** p < 0.01.

SNHG12 directly targets miR-497–5p

To probe the possible downstream mechanism of SNHG12 in BV-induced neurotoxicity, we applied StarBase 2.0 website to predict the potential target microRNAs (miRNAs) for SNHG12. Under the following conditions (CLIP Data: strict stringency≥5; Pan-Cancer: four cancer types), six downstream microRNAs (miR-199a-5p, miR-320a, miR-424–5p, miR-195–5p, miR-1301–3p, and miR-497–5p) were screened by StarBase website. As indicated by RT-qPCR, only miR-497–5p expression was remarkably declined in SNHG12-overexpressed SH-SY5Y cells (Figure 3(A)). According to a previous study by Chen et al., miR-497–5p could aggravate ketamine-induced neuronal injury via inactivating the TrkB/PI3K/Akt pathway,²⁴ suggesting miR-497–5p could exacerbate anesthetic-induced neurotoxicity. Therefore, miR-497–5p was chosen as a target of SNHG12 in this study. The binding site between miR-497–5p and SNHG12 was provided by the StarBase website (Figure 3(B)). Next, miR-497–5p overexpression efficiency in SH-SY5Y cells was verified by RT-qPCR (Figure 3(C)). Dual-luciferase reporter assay manifested that the luciferase activity of SNHG12-WT group was remarkably decreased after miR-497–5p upregulation, while the luciferase activity of SNHG12-MUT group showed no significant difference (Figure 3(D)), confirming miR-497–5p as a downstream target of SNHG12 in SH-SY5Y cells. In addition, RT-qPCR results revealed that miR-497–5p level was upregulated with the increase of BV concentration (Figure 3(E)). Next, SNHG12 was knocked down in SH-SY5Y cells, and the knockdown efficiency was confirmed (Figure 3(F)). The results of RT-qPCR assay disclosed that miR-497–5p expression in BV-induced SH-SY5Y cells was reduced after SNHG12 upregulation and increased after SNHG12 downregulation (Figure 3(G)). Taken together, SNHG12 could negatively regulate miR-497–5p expression in SH-SY5Y cells.

Figure 3.

SNHG12 directly targets miR-497-5p. (A) MiRNA expressions in SH-SY5Y cells transfected with Vector or oe-SNHG12 were detected via RT-qPCR assay. (B) The binding site between miR-497–5p and SNHG12 was provided by the StarBase website. (C) MiR-497–5p expression in SH-SY5Y cells transfected with NC mimics or miR-497–5p mimics was detected via RT-qPCR assay. (D) Dual-luciferase reporter assay was utilized to confirm the interaction between SNHG12 and miR-497–5p. (E) MiR-497–5p expression in SH-SY5Y cells treated with BV at different concentrations (0, 0.5, 1.0, 1.5, or 2.0 mM) was detected via RT-qPCR assay. (F) SNHG12 expression in SH-SY5Y cells transfected with si-NC or si-SNHG12 was detected via RT-qPCR assay. (G) MiR-497–5p expression in BV-treated SH-SY5Y cells transfected with Vector, oe-SNHG12, si-NC, or si-SNHG12 was detected via RT-qPCR. * p < 0.05, ** p < 0.01.

SNHG12 mitigates BV-induced neurotoxicity via miR-497–5p

To study whether SNHG12 regulated BV-induced neurotoxicity via miR-497–5p, SH-SY5Y cells were firstly subject to BV treatment and then transfected with Vector, SNHG12, SNHG12+NC mimics, or SNHG12+miR-497–5p mimics. RT-qPCR results exhibited that miR-497–5p upregulation partially abolished the inhibitory effect of SNHG12 upregulation on miR-497–5p expression (Figure 4(A)). In addition, SNHG12 upregulation promoted the viability of BV-treated SH-SY5Y cells, which was neutralized after miR-497–5p overexpression (Figure 4(B)). Also, miR-497–5p upregulation partly rescued the inhibitory effect of SNHG12 addition on BV-induced SH-SY5Y cell apoptosis (Figure 4(C)). In addition, the suppressive impact of SNHG12 overexpression on BV-induced oxidative damage in SH-SY5Y cells was also neutralized by miR-497–5p amplification, as indicated by the variation of oxidative stress-associated factors (LDH, MDA, SOD, and GSH-Px) (Figure 4(D–G)). Furthermore, the promoting effect of SNHG12 upregulation on BDNF level was reversed by miR-497–5p addition (Figure 4(H)). To sum up, SNHG12 upregulation relieved BV-induced neurotoxicity in SH-SY5Y cells, while miR-497–5p addition partly offset such a mitigative effect, implying SNHG12 regulated BV-induced neurotoxicity in vitro via interaction with miR-497–5p.

Figure 4.

SNHG12 mitigates BV-induced neurotoxicity via miR-497-5p. (A) SH-SY5Y cells were firstly subject to BV treatment and then transfected with Vector, SNHG12, SNHG12+NC mimics, or SNHG12+miR-497–5p mimics, with untreated SH-SY5Y cells as the control group. (B) CCK-8 assay was applied to assess the viability of SH-SY5Y cells in Control, BV+Vector, BV+oe-SNHG12, BV+ oe-SNHG12+NC mimics, or BV+oe-SNHG12+miR-497–5p mimics groups. (C) Flow cytometry assay was applied to detect SH-SY5Y cell apoptosis in each group. Q1 = Necrosis, Q2 = Late apoptosis, Q3 = Early apoptosis, Q4 = Viability. (D–G) The LDH, MDA, SOD, and GSH-P_X levels in SH-SY5Y cells were detected by specific kits. (H) BDNF level in SH-SY5Y cells from each group was detected via RT-qPCR. * p < 0.05, ** p < 0.01.

NLRX1 is directly targeted by miR-497–5p

To further explore the downstream target of miR-497–5p in BV-induced neurotoxicity, four databases (microT, miRanda, miRmap, and PITA) were employed to predict the target of miR-497–5p. 11 candidate genes (FAM189 B, SINHCAF, ZNF622, SPTBN2, AP2B1, COP1, WIPI2, PISD, SSRP1, NLRX1, and KDSR) were screened (Figure 5(A)). It was demonstrated by Chen et al. that NLR family member X1 (NLRX1) upregulation could relieve trauma-induced brain injury by promoting proliferation and decreasing apoptosis in neurons,²⁵ indicating its neuroprotective functions. Therefore, NLRX1 was chosen. The binding site between miR-497–5p and NLRX1 was as shown in Figure 5(B). Dual-luciferase reporter assay revealed that the relative luciferase activity of NLRX1-WT was significantly reduced in the miR-497–5p group (Figure 5(C)). As shown in Figure 5(D), NLRX1 expression was substantially reduced with the increase of BV concentration. Then, miR-497–5p inhibition efficiency was verified by RT-qPCR (Figure 5(E)). As revealed by RT-qPCR assay, NLRX1 level in BV-challenged SH-SY5Y cells was markedly reduced after miR-497–5p upregulation and increased after miR-497–5p silencing (Figure 5(F)). Furthermore, NLRX1 expression in BV-treated SH-SY5Y cells was significantly declined after SNHG12 knockdown and dramatically upregulated after SNHG12 addition (Figure 5(G)). In sum, NLRX1 expression in BV-challenged SH-SY5Y cells was negatively regulated by miR-497–5p and positively regulated by SNHG12.

Figure 5.

NLRX1 is directly targeted by miR-497-5p. (A) The Venn diagram of candidate genes for miR-497–5p predicted by four databases (microT, miRanda, miRmap, and PITA). (B) The binding site between miR-497–5p and NLRX1 was provided by the StarBase website. (C) Dual-luciferase reporter assay was utilized to confirm the interaction between NLRX1 and miR-497–5p. (D) NLRX1 expression in SH-SY5Y cells treated with BV at different concentrations (0, 0.5, 1.0, 1.5, or 2.0 mM) was detected via RT-qPCR assay. (E) MiR-497–5p expression in SH-SY5Y cells transfected with NC inhibitor or miR-497–5p inhibitor was detected via RT-qPCR assay. (F) NLRX1 expression in BV-treated SH-SY5Y cells transfected with NC mimics, miR-497–5p mimics, NC inhibitor, or miR-497–5p inhibitor was detected via RT-qPCR assay. (G) NLRX1 expression in BV-treated SH-SY5Y cells transfected with si-NC, si-SNHG12, Vector, or oe-SNHG12 was detected via RT-qPCR assay. * p < 0.05, ** p < 0.01.

SNHG12/miR-497–5p/NLRX1 axis in BV-induced neurotoxicity

To further explore whether NLRX1 was a downstream regulator of SNHG12/miR-497–5p axis in BV-induced neurotoxicity, SH-SY5Y cells were subject to BV treatment and then transfected with NC inhibitor, miR-497–5p inhibitor, miR-497–5p inhibitor+si-NC, or miR-497–5p inhibitor+si-NLRX1. Firstly, NLRX1 knockdown efficiency in SH-SY5Y cells was confirmed by RT-qPCR (Figure 6(A)). As indicated in RT-qPCR results, miR-497–5p knockdown upregulated NLRX1 expression, which was partly offset by NLRX1 inhibition (Figure 6(B)). Moreover, rescue assays revealed that miR-497–5p downregulation protected SH-SY5Y cells from BV-induced neurotoxicity by increasing cell viability, decreasing cell apoptosis, relieving oxidative damage, and increasing BDNF level; whereas NLRX1 depletion partially reversed these effects (Figure 6(C–I)). In addition, SNHG12 overexpression markedly overturned the suppressive effect of miR-497–5p addition on NLRX1 expression in BV-stimulated SH-SY5Y cells (Figure 6(J)). Taken together, these results indicated that SNHG12 ameliorated BV-induced neurotoxicity via the miR-497–5p/NLRX1 axis.

Figure 6.

SNHG12/miR-497-5p/NLRX1 axis in BV-induced neurotoxicity. (A) NLRX1 expression in SH-SY5Y cells transfected with si-NC or si-NLRX1 was detected via RT-qPCR assay. (B) SH-SY5Y cells were firstly subject to BV treatment and then transfected with NC inhibitor, miR-497–5p inhibitor, miR-497–5p inhibitor+si-NC, or miR-497–5p inhibitor+si-NLRX1, with untreated SH-SY5Y cells as the control group. (C) CCK-8 assay was applied to assess the viability of SH-SY5Y cells in Control, BV+NC inhibitor, BV+miR-497–5p inhibitor, BV+miR-497–5p inhibitor+si-NC, or BV+miR-497–5p inhibitor+si-NLRX1 groups. (D) Flow cytometry assay was applied to detect SH-SY5Y cell apoptosis in each group. Q1 = Necrosis, Q2 = Late apoptosis, Q3 = Early apoptosis, Q4 = Viability. (E–H) The LDH, MDA, SOD, and GSH-P_X levels in SH-SY5Y cells were detected by specific kits. (I) BDNF level in SH-SY5Y cells from each group was detected via RT-qPCR. (J) NLRX1 expression in BV-treated SH-SY5Y cells transfected with NC mimics, miR-497–5p mimics, miR-497–5p mimics+Vector, or miR-497–5p mimics+oe-SNHG12 was detected via RT-qPCR assay. * p < 0.05, ** p < 0.01.

Discussion

BV could cause a lot of adverse drug reactions of which neurotoxicity might lead to permanent and irreversible neurological complications.²⁶ Increasing evidence indicates that lncRNAs play vital roles in BV-induced neurotoxicity. Figure 7 For instance, Fan et al. demonstrated that lincRNA PADNA could alleviate BV-induced neuronal damage by targeting FBXW7 via miR-194.² Guan et al. found that SNHG16 attenuated BV-induced neurotoxicity by negatively regulating miR-132–3p.²⁷ Yuan et al. revealed that ZFAS1 attenuated BV-induced neurotoxicity via the miR-421/ZNF564 pathway.²⁸ Numerous studies have elaborated the essential functions of SNHG12 in human diseases, including atherosclerosis,²⁹ cerebral I/R injury,³⁰ and I/R-induced cardiac dysfunction.³¹ Besides, Wu et al. revealed that SNHG12 could relieve cerebral I/R injury by activating SIRT1/FOXO3a signaling through inhibition of autophagy and oxidative stress.³² In addition, Yuan et al. disclosed that SNHG12 promoted cell proliferation and reduced cell apoptosis in breast cancer via regulating the miR-15a-5/SALL4 cascade.³³ In this work, it was observed that SNHG12 expression in SH-SY5Y cells was decreased with the increase of BV concentration. Consistent with the above studies, SNHG12 upregulation remarkably promoted cell viability, reduced cell apoptosis, and attenuated oxidative damage in BV-treated SH-SY5Y cells. Therefore, it was assumed that SNHG12 could ameliorate BV-induced neurotoxicity in SH-SY5Y cells.

Figure 7.

Schematic diagram shows regulatory mechanisms of SNHG12/miR-497–5p/NLRX1 axis in BV-induced neurotoxicity.

It has been widely recognized that a lncRNA could regulate messenger RNA (mRNA) expression by adsorbing specific miRNA as a competing endogenous RNA (ceRNA).³⁴ Also, the lncRNA/miRNA/mRNA network is deeply involved in neurotoxicity induced by anesthetics, including BV.^23,35 Former studies have proven the promoting role of miR-497–5p in neuronal apoptosis induced by MPP⁺ and ketamine (an anesthetic).^24,36 Herein, it was found that miR-497–5p level in SH-SY5Y cells was upregulated by BV treatment in a dose-dependent manner. In addition, further investigation demonstrated that SNHG12 negatively regulated miR-497–5p and alleviated BV-induced neuronal damage in SH-SY5Y cells through interaction with miR-497–5p. The above results indicated that SNHG12 modulated BV-induced neurotoxicity in vitro via targeting miR-497–5p.

NLRX1 is a member of the nucleotide-binding oligomerization domain, leucine-rich repeat containing protein (NLR) family,³⁷ and uniquely localized to the mitochondria.³⁸ As a negative regulator of inflammatory responses, NLRX1 can negatively regulate inflammatory cytokine production and is deeply involved in the regulation of neuroinflammation.^39,40 As demonstrated by several studies, NLRX1 exerts neuroprotective effects against traumatic brain injury^25,41 and neurodegeneration.⁴² Moreover, Arab et al. revealed that NLRX1 could attenuate oxidative stress and apoptosis via regulating mitochondrial activity.⁴³ Li et al. demonstrated that NLRX1 could alleviate apoptosis and inflammatory responses in myocardial ischemia.⁴⁴ Also, NLRX1 upregulation could substantially improve the viability of lipopolysaccharide-challenged chondrocytes.⁴⁵ In this study, we found that NLRX1 level in SH-SY5Y cells was decreased with the increase of BV concentration. Besides, it was verified that SNHG12 positively regulated NLRX1 expression in BV-treated SH-SY5Y cells via absorbing miR-497–5p. Moreover, NLRX1 knockdown could partially neutralize the effects of miR-497–5p inhibition on BV-mediated cell viability inhibition, cell apoptosis, and oxidative damage in SH-SY5Y cells.

Conclusions

Our investigation demonstrated that SNHG12 relieved BV-induced neurotoxicity in vitro by sponging miR-497–5p to upregulate NLRX1, thereby offering potential molecular targets for the diagnosis and treatment. Nevertheless, the present study lacked in vivo experiments, which should be performed in future studies to further validate the biological functions of the SNHG12/miR-497–5p/NLRX1 regulatory network in BV-induced neurotoxicity.

Footnotes

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iD

Ru Yuan

References

Heavner

. Local anesthetics. Curr Opinion Anaesthesiology 2007; 20: 336–342.

Yuning

Liang

Tenghuan

, et al. Knockdown of lincRNA PADNA promotes bupivacaine-induced neurotoxicity by miR-194/FBXW7 axis. Mol Medicine 2020; 26: 79.

Disma

O'Leary

Loepke

, et al. Anesthesia and the developing brain: A way forward for laboratory and clinical research. Pediatr Anesth 2018; 28: 758–763.

Wang

Slikker

Jr . Strategies and experimental models for evaluating anesthetics: effects on the developing nervous system. Anesth Analgesia 2008; 106: 1643–1658.

Radwan

IAM

Saito

Goto

. The neurotoxicity of local anesthetics on growing neurons: a comparative study of lidocaine, bupivacaine, mepivacaine, and ropivacaine. Anesth Analgesia 2002; 94: 319–324, table of contents.

Wang

Xia

Qiao

, et al. Tetramethylpyrazine attenuated bupivacaine-induced neurotoxicity in SH-SY5Y cells through regulating apoptosis, autophagy and oxidative damage. Drug Design, Development Therapy 2019; 13: 1187–1196.

Ponting

Oliver

Reik

. Evolution and functions of long noncoding RNAs. Cell 2009; 136: 629–641.

Zhang

Zhao

, et al. LncRNA FLVCR1‐AS1 acts as miR‐513c sponge to modulate cancer cell proliferation, migration, and invasion in hepatocellular carcinoma. J Cellular Biochemistry 2018; 119: 6045–6056.

Wei

Wang

. lncRNA MEG3 inhibit proliferation and metastasis of gastric cancer via p53 signaling pathway. Eur Review Medical Pharmacological Sciences 2017; 21: 3850–3856.

10.

Liu

C-Y

Zhang

Y-H

R-B

, et al. LncRNA CAIF inhibits autophagy and attenuates myocardial infarction by blocking p53-mediated myocardin transcription. Nat Communications 2018; 9: 29.

11.

Guo

F-X

, et al. The role of the LncRNA-FA2H-2-MLKL pathway in atherosclerosis by regulation of autophagy flux and inflammation through mTOR-dependent signaling. Cel Death Differ 2019; 26: 1670–1687.

12.

Zeng

Zhu

Liu

, et al. metformin protects against oxidative stress injury induced by ischemia/reperfusion via regulation of the lncRNA-H19/miR-148a-3p/Rock2 Axis. Oxidative Medicine Cellular Longevity 2019; 2019: 8768327.

13.

Huang

. LncRNA MALAT1 is involved in sevoflurane‐induced neurotoxicity in developing rats. J Cellular Biochemistry 2019; 120: 18209–18218.

14.

Yao

Wang

Gao

. LncRNA KCNQ1OT1 Sponges miR-206 to ameliorate neural injury induced by anesthesia via Up-Regulating BDNF. Drug Design, Development Therapy 2020; 14: 4789–4800.

15.

Chi

Jin

, et al. Long Non-Coding RNA BACE1-AS modulates isoflurane-induced neurotoxicity to alzheimer's disease through sponging miR-214-3p. Neurochem Research 2020; 45: 2324–2335.

16.

Zhang

Wang

Yang

, et al. Long noncoding RNA small nucleolar RNA host gene 1 contributes to sevoflurane-induced neurotoxicity through negatively modulating microRNA-181b. Neuroreport 2020; 31: 416–424.

17.

Zhang

Wang

, et al. Downregulation of long noncoding RNA SNHG7 protects against inflammation and apoptosis in Parkinson’s disease model by targeting the miR-425-5p/TRAF5/NF-kappaB axis. J Biochemical Molecular Toxicology 2021; 35: e22867.

18.

Pan

Zhao

Yang

, et al. Overexpression of long non-coding RNA SNHG16 against cerebral ischemia-reperfusion injury through miR-106b-5p/LIMK1 axis. Life Sciences 2020; 254: 117778.

19.

Zhu

Xiao

Wei

, et al. Revealing potential long non-coding RNA biomarkers in lung adenocarcinoma using long non-coding RNA-mediated competitive endogenous RNA network. Braz J Med Biol Res = Revista brasileira de pesquisas medicas e biologicas 2017; 50: e6297.

20.

Yan

Chen

Zhou

, et al. SNHG12 inhibits oxygen-glucose deprivation-induced neuronal apoptosis via the miR-181a-5p/NEGR1 axis. Mol Medicine Reports 2020; 22: 3886–3894.

21.

Yao

Huang

, et al. LncRNA SNHG12 as a potent autophagy inducer exerts neuroprotective effects against cerebral ischemia/reperfusion injury. Biochem Biophysical Research Communications 2019; 514: 490–496.

22.

Yan

Lei

. Long noncoding RNA small nucleolar RNA host gene 12/microRNA-138-5p/nuclear factor I/B regulates neuronal apoptosis, inflammatory response, and oxidative stress in Parkinson’s disease. Bioengineered 2021.

23.

Zhao

. Knockdown of lncRNA MALAT1 alleviates bupivacaine-induced neurotoxicity via the miR-101-3p/PDCD4 axis. Life Sciences 2019; 232: 116606.

24.

Chen

Yan

Xie

, et al. LncRNA LINC00641 Sponges miR-497-5p to ameliorate neural injury induced by anesthesia via Up-Regulating BDNF. Front Molecular Neuroscience 2020; 13: 95.

25.

Chen

Zeng

, et al. Long noncoding RNA NKILA transferred by astrocyte-derived extracellular vesicles protects against neuronal injury by upregulating NLRX1 through binding to mir-195 in traumatic brain injury. Aging 2021; 13: 8127–8145.

26.

Liu

Yang

, et al. Adverse drug reactions to local anesthetics: a systematic review. Oral Surgery, Oral Medicine, Oral Pathology Oral Radiology 2013; 115: 319–327.

27.

Guan

Jiang

. Bupivacaine-induced neurotoxicity is modulated by epigenetic axis of long noncoding RNA SNHG16 and Hsa-miR-132-3p. Neurotoxicity Research 2020; 38: 175–183.

28.

Yuan

Guo

, et al. Long non-coding RNA ZFAS1 alleviates bupivacaine-induced neurotoxicity by regulating the miR-421/zinc finger protein564 (ZNF564) axis. Bioengineered 2021; 12: 5231–5240.

29.

Mao

Liu

Wen

, et al. LncRNA SNHG12 regulates ox-LDL-induced endothelial cell injury by the miR-218-5p/IGF2 axis in atherosclerosis. Cell Cycle 2021; 20: 1561–1577.

30.

Guo

Liu

, et al. Silencing of SNHG12 enhanced the effectiveness of mscs in alleviating ischemia/reperfusion injuries via the PI3K/AKT/mTOR signaling pathway. Front Neuroscience 2019; 13: 645.

31.

Xiao

Chen

, et al. LncRNA SNHG12 downregulates RAGE to attenuate hypoxia-reoxygenation-induced apoptosis in H9c2 cells. Biosci Biotechnology, Biochemistry 2021; 85: 866–873.

32.

Huang

Cai

, et al. LncRNA SNHG12 Improves Cerebral Ischemic-reperfusion Injury by Activating SIRT1/FOXO3a Pathway through I nhibition of Autophagy and oxidative stress. Curr Neurovascular Research 2020; 17: 394–401.

33.

Yuan

, et al. Upregulation of SNHG12 accelerates cell proliferation, migration, invasion and restrain cell apoptosis in breast cancer by enhancing regulating SALL4 expression via sponging miR-15a-5p. Neoplasma 2020; 67: 861–870.

34.

Fan

Wang

Shen

, et al. Identification of lncRNA expression profiles and analysis of ceRNA in the hippocampus of perinatal glyphosate‐exposed mice. Int J Develop Neurosci 2021; 81: 312–323.

35.

Wei

Chen

. LncRNA Neat1/miR-298-5p/Srpk1 Contributes to Sevoflurane-Induced Neurotoxicity. Neurochemical research, 2021.

36.

Zhu

Zhang

Gao

, et al. Silencing of miR-497-5p inhibits cell apoptosis and promotes autophagy in Parkinson's disease by upregulation of FGF2. Environ Toxicology 2021.

37.

Eitas

Chou

W-C

Wen

, et al, The nucleotide-binding leucine-rich repeat (NLR) family member NLRX1 mediates protection against experimental autoimmune encephalomyelitis and represses macrophage/microglia-induced inflammation. J Biol Chem 2014; 289: 4173–4179.

38.

Gharagozloo

Mahmoud

Simard

, et al. NLRX1 inhibits the early stages of CNS inflammation and prevents the onset of spontaneous autoimmunity. PLoS Biology 2019; 17: e3000451.

39.

Wang

Zhang

Yang

, et al. SOD2 mediates curcumin-induced protection against oxygen-glucose deprivation/reoxygenation Injury in HT22 Cells. Evid Based Complementary Alternative Medicine : eCAMeCAM 2019; 2019: 2160642.

40.

Xia

Cui

Wang

, et al. NLRX1 negatively regulates TLR-Induced NF-κB signaling by targeting TRAF6 and IKK. Immunity 2011; 34: 843–853.

41.

Theus

Brickler

Meza

, et al. Loss of NLRX1 exacerbates neural tissue damage and NF-κB signaling following brain injury. J Immunol 2017; 199: 3547–3558.

42.

Imbeault

Mahvelati

Braun

, et al. Nlrx1 regulates neuronal cell death. Mol Brain 2014; 7: 90.

43.

Stokman

Kors

Bakker

, et al. NLRX1 dampens oxidative stress and apoptosis in tissue injury via control of mitochondrial activity. J Exp Med 2017; 214: 2405–2420.

44.

Zhang

, et al. NLRX1 attenuates apoptosis and inflammatory responses in myocardial ischemia by inhibiting MAVS-dependent NLRP3 inflammasome activation. Mol Immunology 2016; 76: 90–97.

45.

Zhao

She

, et al. NLRX1 alleviates lipopolysaccharide-induced apoptosis and inflammation in chondrocytes by suppressing the activation of NF-κB signaling. Int Immunopharmacology 2019; 71: 7–13.

LncRNA SNHG12 ameliorates bupivacaine-induced neurotoxicity by sponging miR-497–5p to upregulate NLRX1

Abstract

Keywords

Introduction

Materials and Methods

Reagents

Cell culture and BV treatment

Cell transfection

CCK-8 assay

Flow cytometry

Determination of oxidative stress-associated factors

RT-qPCR assay

Dual-luciferase reporter assay

Statistical analysis

Results

SNHG12 is lowly expressed in an in vitro model of BV-induced neurotoxicity

SNHG12 upregulation alleviates the neurotoxicity induced by BV treatment in SH-SY5Y cells

SNHG12 directly targets miR-497–5p

SNHG12 mitigates BV-induced neurotoxicity via miR-497–5p

NLRX1 is directly targeted by miR-497–5p

SNHG12/miR-497–5p/NLRX1 axis in BV-induced neurotoxicity

Discussion

Conclusions

Footnotes

Declaration of conflicting interests

Funding

ORCID iD

References